IntroMedic Co., Ltd. announced that it expects to receive KRW 6 billion in funding from FIT Technology Co., Ltd. and another investor
March 02, 2020
Share
IntroMedic Co., Ltd. (KOSDAQ:A150840) announced a private placement of series 11 unregistered coupon unguaranteed private convertible bonds for gross proceeds of KRW 6,000,000,000 on March 3, 2020. The transaction will involve participation from new investors FIT Technology Co., Ltd. and Centrol F&B Co., Ltd. for KRW 3,000,000,000 each. The bonds have yield to maturity of 5.5%. The bonds will mature on April 3, 2023. The bonds are 100% convertible into 2,086,956 shares at a conversion price of KRW 2,875 per share. The start date of conversion period is April 3, 2021 and end date is March 3, 2023. The subscription date is March 3, 2020. The company expects to close the transaction on April 3, 2020. The transaction has been approved by the company’s board of directors.
IntroMedic Co., Ltd. is a Korea-based company mainly engaged in the development, manufacture and distribution of medical equipment. The Companyâs products consist of capsule endoscope, which is used for small intestine check under the brand name MiroCam; disposable endoscope, which is used to detect abnormalities of the esophagus and the stomach under the brand name E.G. Scan, and other accessories, such as abdominal disposable data belts and others. The Company distributes its products within domestic market and to overseas markets.
INTROMEDIC CO., LTD. 